Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study - Takeaways - MDSpire

Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study

  • By

  • Neeltje Steeghs

  • Carlos Gomez-Roca

  • Iphigénie Korakis

  • Eelke Gort

  • Hilde De Winter

  • Nina Stojcheva

  • Vaia Stavropoulou

  • Jennifer Krieg

  • Paul Baverel

  • Elena Fernandez

  • Ana Maria Florescu

  • Lea Hoenig

  • Michael Peter Sanderson

  • Vladimir Kirkin

  • Philippe Legenne

  • Philippe Alexandre Cassier

  • May 1, 2026

  • 0 min

Share

  • 1

    MP0317 is a bispecific DARPin designed to activate CD40 specifically in the tumor microenvironment, reducing systemic toxicity compared to traditional antibodies.

  • 2

    The phase 1 study enrolled 46 patients with advanced solid tumors, primarily colorectal and pancreatic cancers, who were heavily pretreated.

  • 3

    MP0317 was administered intravenously at various dose levels, with patients receiving treatment for a median of 5 weeks.

  • 4

    A total of 415 treatment-emergent adverse events were reported, with 118 classified as treatment-related, mostly mild to moderate.

  • 5

    No treatment-related adverse events greater than grade 3 were observed, indicating a favorable safety profile for MP0317.

Original Source(s)

Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study

  • by Neeltje Steeghs, Carlos Gomez-Roca, Iphigénie Korakis, Eelke Gort, Hilde De Winter, Nina Stojcheva, Vaia Stavropoulou, Jennifer Krieg, Paul Baverel, Elena Fernandez, Ana Maria Florescu, Lea Hoenig, Michael Peter Sanderson, Vladimir Kirkin, Philippe Legenne, Philippe Alexandre Cassier

  • May 1, 2026

Related Content

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

High-grade astrocytoma with piloid features: a case report of comprehensive management

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report